Mobilization of Leukemic Cells Using Plerixafor as Part of a Myeloablative Preparative Regimen for Patients With AML Undergoing Allografting: Assessment of Feasibility and Efficacy.

Trial Profile

Mobilization of Leukemic Cells Using Plerixafor as Part of a Myeloablative Preparative Regimen for Patients With AML Undergoing Allografting: Assessment of Feasibility and Efficacy.

Completed
Phase of Trial: Phase I/II

Latest Information Update: 17 Oct 2015

At a glance

  • Drugs Plerixafor (Primary) ; Busulfan; Fludarabine
  • Indications Acute myeloid leukaemia
  • Focus Adverse reactions
  • Most Recent Events

    • 20 Jul 2010 Actual initiation date (July 2010) added as reported by ClinicalTrials.gov.
    • 20 Jul 2010 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
    • 18 Jun 2010 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top